These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26555134)

  • 1. Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success.
    Daniels JF; Khogali M; Mohr E; Cox V; Moyo S; Edginton M; Hinderaker SG; Meintjes G; Hughes J; De Azevedo V; van Cutsem G; Cox HS
    PLoS One; 2015; 10(11):e0142873. PubMed ID: 26555134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa.
    Mohr E; Cox V; Wilkinson L; Moyo S; Hughes J; Daniels J; Muller O; Cox H
    Trans R Soc Trop Med Hyg; 2015 Jul; 109(7):425-32. PubMed ID: 25979526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of mortality and treatment success of multi-drug resistant and Rifampicin resistant tuberculosis in Zimbabwe: a retrospective cohort analysis of patients initiated on treatment during 2010 to 2015.
    Matambo R; Nyandoro G; Sandy C; Nkomo T; Mutero-Munyati S; Mharakurwa S; Chikaka E; Ngwenya M; Ndongwe G; Pepukai VM
    Pan Afr Med J; 2021; 39():128. PubMed ID: 34527144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda.
    Habimana DS; Ngabonziza JCS; Migambi P; Mucyo-Habimana Y; Mutembayire G; Byukusenge F; Habiyambere I; Remera E; Mugwaneza P; Mwikarago IE; Mazarati JB; Turate I; Nsanzimana S; Decroo T; de Jong CB
    Am J Trop Med Hyg; 2021 May; 105(1):47-53. PubMed ID: 33999845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho.
    Satti H; McLaughlin MM; Hedt-Gauthier B; Atwood SS; Omotayo DB; Ntlamelle L; Seung KJ
    PLoS One; 2012; 7(10):e46943. PubMed ID: 23115633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of cure among HIV co-infected multidrug-resistant TB patients at Sizwe Tropical Disease Hospital Johannesburg, South Africa.
    Umanah TA; Ncayiyana JR; Nyasulu PS
    Trans R Soc Trop Med Hyg; 2015 May; 109(5):340-8. PubMed ID: 25787727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting.
    Gandhi NR; Andrews JR; Brust JC; Montreuil R; Weissman D; Heo M; Moll AP; Friedland GH; Shah NS
    Int J Tuberc Lung Dis; 2012 Jan; 16(1):90-7. PubMed ID: 22236852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa.
    Umanah T; Ncayiyana J; Padanilam X; Nyasulu PS
    BMC Infect Dis; 2015 Oct; 15():478. PubMed ID: 26511616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistently high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa.
    Schnippel K; Firnhaber C; Ndjeka N; Conradie F; Page-Shipp L; Berhanu R; Sinanovic E
    Int J Tuberc Lung Dis; 2017 Oct; 21(10):1106-1111. PubMed ID: 28911353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial.
    Padayatchi N; Abdool Karim SS; Naidoo K; Grobler A; Friedland G
    Int J Tuberc Lung Dis; 2014 Feb; 18(2):147-54. PubMed ID: 24429305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High mortality among patients hospitalized for drug-resistant tuberculosis with acquired second-line drug resistance and high HIV prevalence.
    Anderson K; Pietersen E; Shepherd BE; Bian A; Dheda K; Warren R; Sterling TR; van der Heijden YF
    HIV Med; 2022 Nov; 23(10):1085-1097. PubMed ID: 35608016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: a systematic review and meta-analysis.
    Chem ED; Van Hout MC; Hope V
    BMC Infect Dis; 2019 Aug; 19(1):723. PubMed ID: 31420021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Declining prevalence of drug-resistant tuberculosis among HIV/tuberculosis co-infected patients receiving antiretroviral therapy.
    Sungkanuparph S; Eampokalap B; Chottanapund S; Bed ST; Manosuthi W
    J Med Assoc Thai; 2007 May; 90(5):884-8. PubMed ID: 17596041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses.
    Pepper DJ; Rebe K; Morroni C; Wilkinson RJ; Meintjes G
    PLoS One; 2009; 4(2):e4520. PubMed ID: 19229341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa.
    Cox H; Ramma L; Wilkinson L; Azevedo V; Sinanovic E
    Trop Med Int Health; 2015 Oct; 20(10):1337-45. PubMed ID: 25975868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015.
    Matambo R; Takarinda KC; Thekkur P; Sandy C; Mharakurwa S; Makoni T; Ncube R; Charambira K; Zishiri C; Ngwenya M; Nyathi S; Chiteka A; Chikaka E; Mutero-Munyati S
    PLoS One; 2020; 15(4):e0230848. PubMed ID: 32353043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa.
    Lawn SD; Myer L; Bekker LG; Wood R
    AIDS; 2007 Jan; 21(3):335-41. PubMed ID: 17255740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa.
    Evans D; Sineke T; Schnippel K; Berhanu R; Govathson C; Black A; Long L; Rosen S
    BMC Health Serv Res; 2018 Dec; 18(1):973. PubMed ID: 30558670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa.
    Salaam-Dreyer Z; Streicher EM; Sirgel FA; Menardo F; Borrell S; Reinhard M; Doetsch A; Cudahy PGT; Mohr-Holland E; Daniels J; Dippenaar A; Nicol MP; Gagneux S; Warren RM; Cox H
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0036421. PubMed ID: 34460307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.